MX339533B - Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp). - Google Patents

Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp).

Info

Publication number
MX339533B
MX339533B MX2012006115A MX2012006115A MX339533B MX 339533 B MX339533 B MX 339533B MX 2012006115 A MX2012006115 A MX 2012006115A MX 2012006115 A MX2012006115 A MX 2012006115A MX 339533 B MX339533 B MX 339533B
Authority
MX
Mexico
Prior art keywords
methods
dac hyp
compositions
hyp compositions
dac
Prior art date
Application number
MX2012006115A
Other languages
English (en)
Other versions
MX2012006115A (es
Inventor
J Yun Tso
Taymar Hartman
Paul W Sauer
John W Burky
Mark C Wesson
Ping Y Huang
Thomas J Robinson
Braeden Partridge
John E Burky
Original Assignee
Abbvie Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotechnology Ltd filed Critical Abbvie Biotechnology Ltd
Publication of MX2012006115A publication Critical patent/MX2012006115A/es
Publication of MX339533B publication Critical patent/MX339533B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición que comprende daclizumab, en el cual el daclizumab tiene un perfil de glicosilación ligada a N en el cual el AUC total de los máximos en el perfil que corresponden a glicosilos de manosa no fucosilada es menos de aproximadamente 6% del AUC total de todos los máximos en el perfil, en donde el perfil de glicosilación ligada a N se determina: (a) librando oligosacáridos ligados a N a partir del anticuerpo; (b) derivado los oligosacáridos ligados a N con una marca fluorescente; (c) separando los oligosacáridos ligados a N del anticuerpo; (d) resolviendo lo oligosacáridos ligados a N; y (e) detectando la marca fluorescente .
MX2012006115A 2011-05-27 2012-05-25 Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp). MX339533B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161490998P 2011-05-27 2011-05-27

Publications (2)

Publication Number Publication Date
MX2012006115A MX2012006115A (es) 2012-12-04
MX339533B true MX339533B (es) 2016-05-30

Family

ID=46177353

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006115A MX339533B (es) 2011-05-27 2012-05-25 Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp).

Country Status (10)

Country Link
US (7) US20120301429A1 (es)
EP (1) EP2527429A3 (es)
JP (4) JP6055615B2 (es)
CN (2) CN107090040A (es)
AU (4) AU2012203095B2 (es)
BR (1) BR102012012673A8 (es)
CA (1) CA2777978A1 (es)
MX (1) MX339533B (es)
RU (2) RU2018119112A (es)
SG (1) SG185920A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018119112A (ru) 2011-05-27 2018-11-07 Эббви Байотекнолоджи Лтд. Композиции и способы на основе dac hyp
EP2741773A1 (en) * 2011-08-08 2014-06-18 AbbVie Biotherapeutics Inc. Methods of treating progressive forms of multiple sclerosis
AU2011382454B2 (en) * 2011-11-30 2017-02-23 Abbvie Biotechnology Ltd Vectors and host cells comprising a modified SV40 promoter for protein expression
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2015034566A1 (en) * 2013-09-04 2015-03-12 Emd Millipore Corporation Protein a chromatography
GB201503578D0 (en) * 2015-03-03 2015-04-15 Ge Healthcare Bio Sciences Ab Sanitization method for affinity chromatography matrices
WO2016154290A1 (en) 2015-03-23 2016-09-29 Alexion Pharmaceuticals, Inc. Virus filtration
IL257420B (en) 2015-08-12 2022-08-01 Pfizer Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
JP6937309B2 (ja) 2016-01-27 2021-09-22 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド ハイブリッドプロモーターおよびその使用
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
WO2018027195A1 (en) * 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
KR102586771B1 (ko) * 2017-01-30 2023-10-11 리제너론 파마슈티칼스 인코포레이티드 크로마토그래피에서 바이오버든을 감소시키기 위한 조성물 및 방법
WO2019126554A1 (en) * 2017-12-21 2019-06-27 Genzyme Corporation Methods for enhanced removal of impurities during protein a chromatography
CN113747960A (zh) 2019-04-17 2021-12-03 百时美施贵宝公司 用于再生色谱树脂的方法
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
JP2022542317A (ja) * 2019-08-01 2022-09-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ウイルス不活性化のための方法
EP3931303A1 (en) 2019-12-06 2022-01-05 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
JP7631742B2 (ja) * 2020-11-10 2025-02-19 東ソー株式会社 ペプチド性リガンド固定化カラムの洗浄方法
BR112023017717A2 (pt) * 2021-05-03 2024-01-09 Boehringer Ingelheim Int Método para produção de espesolimabe
CN114181300A (zh) * 2021-12-20 2022-03-15 方坦思(上海)生物医药有限公司 一种高纯度单克隆抗体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430566A (en) * 1974-11-15 1976-03-31 Nestel Sa Isolation of proteins
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
RU2318537C2 (ru) * 2001-04-06 2008-03-10 Юниверсити Оф Бристоль Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам
JP2005325133A (ja) * 2001-10-15 2005-11-24 Kirin Brewery Co Ltd 抗ｈｌａ−ｄｒ抗体の利用
US20040002135A1 (en) * 2002-03-28 2004-01-01 Sauer Paul W. Adapted NS0 cell lines with the ability to grow under glutamine-free conditions
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1614693A4 (en) * 2003-03-31 2006-07-19 Kirin Brewery Purification of a human monoclonal antibody and human polyclonal antibody
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CA2655246A1 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
WO2009017491A1 (en) * 2006-06-14 2009-02-05 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
WO2008004931A1 (en) * 2006-07-06 2008-01-10 Ge Healthcare Bio-Sciences Ab Disinfection/sanitation method where the material is treated with a solution comprising benzyl alcohol and c2-3 alcohol
AU2009223054A1 (en) * 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced ADCC function
EP2318437A2 (en) * 2008-08-28 2011-05-11 Abbott Biotherapeutics Corp. Method for treating multiple sclerosis patients with anti-il2r antibodies
US20120329709A1 (en) * 2009-05-26 2012-12-27 Brian Edward Collins Production of glycoproteins
EP2438185A4 (en) 2009-06-05 2016-10-05 Momenta Pharmaceuticals Inc METHODS FOR MODULATING FUCOSYLATION OF GLYCOPROTEINS
CN102574911B (zh) * 2009-08-07 2017-06-06 Emd密理博公司 从样品的一或多种杂质中纯化靶蛋白的方法
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
RU2018119112A (ru) * 2011-05-27 2018-11-07 Эббви Байотекнолоджи Лтд. Композиции и способы на основе dac hyp

Also Published As

Publication number Publication date
AU2016202873B2 (en) 2018-02-22
US9260528B2 (en) 2016-02-16
US9340619B2 (en) 2016-05-17
AU2016202873A1 (en) 2016-05-26
US20200157230A1 (en) 2020-05-21
US20150274832A1 (en) 2015-10-01
US20120301429A1 (en) 2012-11-29
US20150197573A1 (en) 2015-07-16
US20180127506A1 (en) 2018-05-10
AU2020202298A1 (en) 2020-04-23
EP2527429A2 (en) 2012-11-28
CN107090040A (zh) 2017-08-25
CA2777978A1 (en) 2012-11-27
US20150203583A1 (en) 2015-07-23
JP2020078348A (ja) 2020-05-28
EP2527429A3 (en) 2013-10-30
BR102012012673A8 (pt) 2021-02-17
JP2016210796A (ja) 2016-12-15
CN102796705A (zh) 2012-11-28
JP2012244993A (ja) 2012-12-13
MX2012006115A (es) 2012-12-04
US9676860B2 (en) 2017-06-13
AU2012203095A1 (en) 2012-12-13
US9815903B2 (en) 2017-11-14
AU2018200654A1 (en) 2018-02-15
RU2661764C2 (ru) 2018-07-19
BR102012012673A2 (pt) 2015-11-17
US20170247461A1 (en) 2017-08-31
SG185920A1 (en) 2012-12-28
RU2012121876A (ru) 2013-11-27
RU2018119112A (ru) 2018-11-07
AU2012203095B2 (en) 2016-02-04
JP6055615B2 (ja) 2016-12-27
JP2018134091A (ja) 2018-08-30

Similar Documents

Publication Publication Date Title
MX339533B (es) Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp).
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
PH12015502839B1 (en) Antiviral compounds
AU340307S (en) Toy
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
IN2015DN00127A (es)
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
SI3321355T1 (sl) Postopki in sestavki za klinično izpeljavo alogenske celice in terapevtske uporabe
IN2014CN03555A (es)
IN2014DN06104A (es)
IL227919A0 (en) Methods and preparations for the production of stem cells related to highly active nerve cells specific to the patient
MY168300A (en) Pharmaceutical Composition for Inhalation
IN2014CN03072A (es)
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
IN2014DN03298A (es)
ZA201209204B (en) Methods of making and using electrode compositions and articles
MX347541B (es) Analogos de acido sialico.
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
EP2673048A2 (en) Treatment of bipolar disorder
IN2014DN03010A (es)
IL228439A0 (en) Gallium compounds, medical preparations and methods of use
MX337206B (es) Variantes de factor neurotrófico derivado de celulas gliales humanas.
EP2938329A4 (en) METHODS AND COMPOSITIONS FOR OXYBUTYNINE ADMINISTRATION
IL231490A0 (en) Preparations and methods for the production and use of human cholinesterases

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ROCK-TENN SHARED SERVICES, LLC.*

GB Transfer or rights

Owner name: ABBVIE BIOTECHNOLOGY LTD.*

FG Grant or registration